Evidence map›Paper›PMID 41024951›Full record

ArticleWorld journal of nephrology2025

Unmasking the silent epidemic: Mortality trends in diabetic nephropathy.

Mauricio Alvarez

Abstract readLetter
In one paragraph

Article in World journal of nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Mauricio AlvarezDepartment of Endocrinology, Hospital Militar Central, Bogota 110221, Distrito Capital de Bogotá, Colombia. mauricioalvarez613@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes mellitus is a major contributor to kidney failure, with diabetic nephropathy being a common microvascular complication. The increasing prevalence of diabetes and its complications suggests a rise in associated morbidity and mortality. Recent studies highlight increased mortality related to diabetic kidney disease, with disparities across demographic and geographic groups. Novel pharmacological treatments, including sodium-glucose cotransporter 2 inhibitors, non-steroidal mineralocorticoid receptor antagonists, and glucagon-like peptide-1 agonists, offer promise in slowing disease progression and reducing renal mortality. However, the growing epidemics of obesity and diabetes necessitate prioritizing public health policies focused on primary and secondary prevention, along with comprehensive multidisciplinary care.

Indexed as

Chronic kidney diseaseDiabetic nephropathyGlucagon-like peptide-1 agonistsMineralocorticoid receptor antagonistsMortalityPreventionPublic health policySodium-glucose cotransporter 2 inhibitors

Identifiers

PMID41024951
PMCPMC12476721

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.